|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Wendy Niebler, Shire

S

Wendy Niebler

Vice President, Global Medical Affairs, ADHD, Shire

EDUCATION: DO from Ohio University College ofOsteopathic Medicine, MBA from St. Joseph's University

ACCOMPLISHMENT: Designed Cephalon's largest global clinical program in under two years

On joining the pharma industry:

I started out as a physician in private practice. But the scientific aspect of clinical trial work motivated me to join Cephalon, because I had a chance to not only run, but design, clinical trials. It was an opportunity of a lifetime. As a physician going to industry, you can miss that day-to-day contact with patients. But it's reassuring to know you can impact patients even in a wider sense.

Wendy Niebler

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.